We serve Chemical Name:3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile CAS:395100-12-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile
CAS.NO:395100-12-6
Synonyms:3-(4-Fluoro-phenyl)-1H-indazole-5-carbonitrile;3-(4-fluorophenyl)-1H-5-indazolecarbonitrile;1H-Indazole-5-carbonitrile,3-(4-fluorophenyl)
Molecular Formula:C14H8FN3
Molecular Weight:237.23200
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.38
Index of Refraction:
PSA:52.47000
Exact Mass:237.07000
LogP:3.24068
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-(4-Fluoro-phenyl)-1H-indazole-5-carbonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Indazole-5-carbonitrile,3-(4-fluorophenyl) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(4-fluorophenyl)-1H-5-indazolecarbonitrile Use and application,1H-Indazole-5-carbonitrile,3-(4-fluorophenyl) technical grade,usp/ep/jp grade.
Related News: The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile manufacturer The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term. 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile supplier The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term. 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile vendor The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile factory The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward.
